All In Biotech

Drug Trial Radar · NCT00002719

Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)

Last checked: Nov 20, 2026Latest source record: Jul 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 1995

Primary completion

Nov 2001

Sponsor

Sponsor type
Research network
Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
First posted
Apr 29, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 61 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in the bone marrow or peripheral blood and may help a person's immune system recover after chemotherapy and radiation therapy. Combining more than one drug and giving drugs in different ways may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without G-CSF in treating older patients with acute myeloid leukemia.

Conditions

  • Leukemia
  • Neutropenia

Interventions

  • filgrastimBiological

  • amsacrineDrug

  • carmustineDrug

  • cytarabineDrug

  • etoposideDrug

  • idarubicinDrug

  • mitoxantrone hydrochlorideDrug

  • peripheral blood stem cell transplantationProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Azienda Policlinico Umberto Primo

    Rome, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.